• NuWays reiterated its Buy rating on Gallmetzer Healthcare on November 2, 2026, maintaining a 12-month price target of EUR 4.4.
• Intermedical Pharma's first product sales are expected in Q4 2027, with full-year revenue forecast at EUR 1.9 million.
• Through fiscal 2030, NuWays projects cumulative revenue potential of EUR 20.5 million and EBITDA contributions of EUR 5.7 million.
• The shares moved to continuous trading effective November 2 to improve investor access; sustained liquidity gains depend on trading volumes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gallmetzer Healthcare S.p.A. published the original content used to generate this news brief via EQS News (Ref. ID: rc_27262) on November 02, 2026, and is solely responsible for the information contained therein.